Template:Ceftazidime: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ceftazidime|{{fontcolor|#6C7B8B|Ceftazidime}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ceftazidime|{{fontcolor|#6C7B8B|Ceftazidime}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | FORATZ<sup>®</sup>,TAZICEF<sup>®</sup,CEFTAZIDIME<sup>®</sup FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | FORATZ<sup>®</sup>,TAZICEF<sup>®</sup>,CEFTAZIDIME<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime description|Description]] | ||
| Line 20: | Line 20: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime compatibility and stability|Compatibility and stability]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime directions for use|Directions for use]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftazidime how supplied|How Supplied]] | ||
Latest revision as of 17:59, 30 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| Directions for use |
| How Supplied |
| Labels and Packages |